|
1）Okamura H, Doi M, Fustin JM, et al. Mammalian circadian clock system: Molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev. 2010; 62: 876-84
|
|
|
|
2）米国睡眠医学会．睡眠障害国際分類第2版，診断とコードの手引き．日本睡眠学会, 診断分類委員会, 訳. 東京: 医学書院, 2010
|
|
|
|
|
|
3）鰤岡直人．体内時計と睡眠時無呼吸症候群．呼と循. 2013; 61: 746-54
|
|
|
|
|
4）Yagita K, Horie K, Koinuma S, et al. Development of the circadian oscillator during differentiation of mouse embryonic stem cells in vitro. Proc Natl Acad Sci U S A. 2010; 107: 3846-51
|
|
|
|
|
|
5）Toh KL, Jones CR, He Y, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 2001; 291: 1040-3
|
|
|
|
|
|
6）Xu Y, Padiath QS, Shapiro RE, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005; 434: 640-4
|
|
|
|
|
|
7）海老澤尚．体内時計の分子機構と睡眠障害．時間薬理学による最新の治療戦略，大戸茂弘，編，東京: 医薬ジャーナル; 2013. p.172-81
|
|
|
|
|
|
8）Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev. 2010; 62: 979-1001
|
|
|
|
|
|
9）Huang W, Ramsey KM, Marcheva B, et al. Circadian rhythms, sleep, and metabolism. J Clin Invest. 2011; 121: 2133-41
|
|
|
|
|
|
10）Takeda N, Maemura K. Cardiovascular disease, chronopharmacotherapy, and the molecular clock. Adv Drug Deliv Rev. 2010; 62: 956-66
|
|
|
|
|
|
11）von Känel R, Natarajan L, Ancoli-Israel S, et al. Day/Night rhythm of hemostatic factors in obstructive sleep apnea. Sleep. 2010; 33: 371-7
|
|
|
|
|
|
12）Maemura K, Takeda N, Nagai R. Circadian rhythms in the CNS and peripheral clock disorders: role of the biological clock in cardiovascular diseases. J Pharmacol Sci. 2007; 103: 134-8
|
|
|
|
|
13）Minami Y, Horikawa K, Akiyama M, et al. Restricted feeding induces daily expression of clock genes and Pai-1 mRNA in the heart of Clock mutant mice. FEBS Lett. 2002; 526: 115-8
|
|
|
|
|
|
14）Doi M, Takahashi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 2010; 16: 67-74
|
|
|
|
|
|
15）Kamdar BB, Tergas AI, Mateen FJ, et al. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 138: 291-301
|
|
|
|
|
|
16）Martino TA, Oudit GY, Herzenberg AM, et al. Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am J Physiol Regul Integr Comp Physiol. 2008; 294: R1675-83
|
|
|
|
|
|
17）Coy TV, Dimsdale JE, Ancoli-Israel S, et al. Sleep apnoea and sympathetic nervous system activity: a review. J Sleep Res. 1996; 5: 42-50
|
|
|
|
|
|
18）Marrone O, Riccobono L, Salvaggio A, et al. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest. 1993; 103: 722-7
|
|
|
|
|
|
19）Ziegler MG, Mills PJ, Loredo JS, et al. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest. 2001; 120: 887-93
|
|
|
|
|
|
20）Burioka N, Fukuoka Y, Koyanagi S, et al. Asthma: Chronopharmacotherapy and the molecular clock. Adv Drug Deliv Rev. 2010; 62: 946-55
|
|
|
|
|
|
21）Komoto S, Kondo H, Fukuta O, et al. Comparison of β-adrenergic and glucocorticoid signaling on clock gene and osteoblast-related gene expressions in human osteoblast. Chronobiol Int. 2012; 29: 66-74
|
|
|
|
|
|
22）Akiyama M, Minami Y, Kuriyama K, et al. MAP kinase-dependent induction of clock gene expression by alpha 1-adrenergic receptor activation. FEBS Lett. 2003; 542: 109-14
|
|
|
|
|
|
23）Burioka N, Koyanagi S, Endo M, et al. Clock gene dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J. 2008; 32: 105-12
|
|
|
|
|
|
24）Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation. 2005; 112: 2660-7
|
|
|
|
|
|
25）Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/ reoxygenation. Biochem Biophys Res Commun. 2007; 355: 728-33
|
|
|
|
|
|
26）Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26: 203-34
|
|
|
|
|
|
27）Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol. 2010; 7: 677-85
|
|
|
|
|
|
28）Kent BD, Ryan S, McNicholas WT. Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity. Respir Physiol Neurobiol. 2011; 178: 475-81
|
|
|
|
|
|
29）Takahashi K, Chin K, Nakamura H, et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal. 2008; 10: 715-26
|
|
|
|
|
|
30）Takahashi K, Chin K, Akamizu T, et al. Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment. Respirology. 2008; 13: 810-6
|
|
|
|
|
|
31）Burioka N, Koyanagi S, Fukuoka Y, et al. Influence of intermittent hypoxia on the signal transduction pathways to inflammatory response and circadian clock regulation. Life Sci. 2009; 85: 372-8
|
|
|
|
|
|
32）Panda S, Antoch MP, Miller BH, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002; 109: 307-20
|
|
|
|
|
|
33）Kripke DF, Shadan FF, Dawson A, et al. Genotyping sleep disorders patients. Psychiatry Investig. 2010; 7: 36-42
|
|
|
|
|